Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

SOUTH JORDAN, Utah, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2023, after the close of the stock market on Thursday, October 26, 2023.

Merit Medical Systems to Announce Third Quarter 2023 Results on October 26, 2023

Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.

Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services

Advanced design complements comprehensive drainage portfolio, expanding compassionate at-home treatment options to more patients Advanced design complements comprehensive drainage portfolio, expanding compassionate at-home treatment options to more patients

Merit Medical Launches the Aspira® Evacuated Drainage Bottle

Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.

Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study

SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit's WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) to percutaneous transluminal angioplasty for treatment of stenosis/occlusion in the venous outflow circuit in patients undergoing hemodialysis.

Merit Medical's WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study Completes Enrollment

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.

Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q2 2023 Earnings Conference Call July 25, 2023 5:00 AM ET Company Participants Fred Lampropoulos - Chairman and Chief Executive Officer Raul Parra - Chief Financial Officer Brian Lloyd - Chief Legal Officer and Corporate Secretary Conference Call Participants Steve Lichtman - Oppenheimer & Company Jayson Bedford - Raymond James Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Mike Matson - Needham & Company Jim Sidoti - Sidoti & Company Michael Petusky - Barrington Research Operator Welcome to the Second Quarter of Fiscal Year 2023 Earnings Conference Call for Merit Medical Systems, Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Mr.

Merit Medical Systems, Inc. (MMSI) Q2 2023 Earnings Call Transcript

Merit Medical (MMSI) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.

Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates

*  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results For Second Quarter June 30, 2023

Medtronic

Patterson Companies

Patterson Companies and Medtronic have above-average dividends. Merit Medical Systems and Medtronic have been active in growing revenue through acquisitions.

3 Top Healthcare Stocks to Buy for July

SOUTH JORDAN, Utah, July 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2023, after the close of the stock market on Tuesday, July 25, 2023.

Merit Medical Systems to Announce Second Quarter 2023 Results On July 25, 2023

Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.

Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View

SOUTH JORDAN, Utah, June 08, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced it has completed the acquisition of a portfolio of dialysis catheter products and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. for a total cash consideration of $100 million. Merit also announced the recent acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc. for a total cash consideration of $32.5 million.

Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc.

Credit agreement includes a revolving credit facility of up to $700 million and a term loan facility of up to $150 million Credit agreement includes a revolving credit facility of up to $700 million and a term loan facility of up to $150 million

Merit Medical Announces New Five-Year Senior Secured Credit Agreement

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?

Why Is Merit Medical (MMSI) Down 1% Since Last Earnings Report?

Merit Medical brought in another strong quarter from top-bottom lines for Q1 FY'23. The firm continues adding value for shareholders, throwing off piles of cash in doing so.

Merit Medical: To Unlock Further Risk Capital In FY 2023

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

Does Merit Medical (MMSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Merit Medical (MMSI) is a Great Momentum Stock: Should You Buy?

Merit Medical Systems, Inc. (MMSI) Q1 2023 Earnings Call Transcript.

Merit Medical Systems, Inc. (MMSI) Q1 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Merit Medical (MMSI) Q1 Earnings: A Look at Key Metrics

Merit Medical (MMSI) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.53 per share a year ago.

Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates

Q1 2023 reported revenue of $297.6 million, up 8.0% compared to Q1 2022 Q1 2023 constant currency revenue, organic* up 9.8% compared to Q1 2022 Q1 2023 GAAP operating margin of 8.9%, compared to 5.5% in Q1 2022 Q1 2023 non-GAAP operating margin* of 16.1%, compared to 14.6% in Q1 2022 Q1 2023 GAAP EPS $0.36, compared to $0.18 in Q1 2022 Q1 2023 non-GAAP EPS* of $0.64, compared to $0.53 in Q1 2022 *  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for First Quarter March 31, 2023

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

News for Merit Medical Systems Stock (MMSI)